CardioMech AS

📍 Trondheim, Norway🗓 Founded 2015👥 10 employees💰 Last funded 2025
Medical Equipment Manufacturing🌐 cardiomech.com
Website LinkedIn
Mitral Regurgitation is the third most common cardiovascular disease that occurs when there is backward flow of blood across the mitral valve. It is highly prevalent, debilitating for patients, and deadly if untreated. The market is expected to be larger than the TAVR market, currently a $6B market. The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. This catheter-based therapy is intended to be a simple and straightforward procedure and an alternative therapy option for both patients eligible for open-heart surgery and those considered surgically ineligible. Therefore, the CardioMech device can potentially reduce the need for open-heart surgery and may lessen the need for watchful waiting in younger and healthier patients. Caution: Investigational device. Limited by law to investigational use.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2015
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Norway
2
Frequently asked questions
Who invested in CardioMech AS?
CardioMech AS has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did CardioMech AS last raise funding?
The most recent investment in CardioMech AS recorded on gritt.io was in 2025.
When was CardioMech AS founded?
CardioMech AS was founded in 2015.
What industry is CardioMech AS in?
CardioMech AS operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is CardioMech AS based?
CardioMech AS is headquartered in Trondheim, Norway.